A watchdog advisory panel, meeting at HMS, concluded Tuesday that a new class of powerful cholesterol-lowering drugs did not offer reasonable value to most patients given their high price tags. Jason Wasfy (Mass General) and Steven Pearson (Harvard Pilgrim Health Care) are quoted.
